{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Genprex, Inc."},"Symbol":{"label":"Symbol","value":"GNPX"},"Address":{"label":"Address","value":"3300 BEE CAVE ROAD,SUITE 650-227, AUSTIN, Texas, 78746, United States"},"Phone":{"label":"Phone","value":"+1 877 774-4679"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral OncoprexÂ® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor."},"CompanyUrl":{"label":"Company Url","value":"https://www.genprex.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Kate Combs","title":"Senior Director-Clinical Operations"},{"name":"Mark S. Berger","title":"Chief Medical Officer"},{"name":"Omar Fernandez","title":"Director-IT"},{"name":"Ryan M. Confer","title":"President, Chief Executive Officer, CFO & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}